TCOV
TCRT icon

Trust Company of Vermont’s Alaunos Therapeutics TCRT Stock Holding History

Trust Company of Vermont’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1
Closed -$4 – 1107
2024
Q2 		$4 Buy
+1
New +$12 ﹤0.01% 898

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
SWM
Sugarloaf Wealth Management Duluth, Georgia $529M AUM 14.14% 1-Year Est. Return

Trust Company of Vermont's TCRT Position: Q3 2024 in Review

Trust Company of Vermont sold out of Alaunos Therapeutics (TCRT) in Q3 2024, closing a stake of 1 share — an estimated $4 sold.

Trust Company of Vermont first reported a position in TCRT in Q2 2024 and held it in 1 quarter. The position peaked at $4 in Q2 2024. 29 funds tracked by Wall St. Rank hold TCRT as of Q3 2024.

  • Trust Company of Vermont reported no remaining Alaunos Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Trust Company of Vermont sold 1 Alaunos Therapeutics share in Q3 2024, an estimated $4.
  • Trust Company of Vermont first reported a position in Alaunos Therapeutics in Q2 2024 and held it in 1 quarter.
  • Trust Company of Vermont's Alaunos Therapeutics position peaked at $4 in Q2 2024.
  • 29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2024.

Based on Trust Company of Vermont's 13F filing for Q3 2024, filed 16 Oct 2024.